These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 23528414

  • 41. Scope and practicality of in vivo testing for adventitious agents.
    Whiteman MD.
    Dev Biol (Basel); 2006; 123():147-52; discussion 183-97. PubMed ID: 16566442
    [Abstract] [Full Text] [Related]

  • 42. [Requirements on the production and testing of sera and vaccines].
    Bonin O.
    Fortschr Med; 1977 Jun 16; 95(23):1541-8. PubMed ID: 881153
    [Abstract] [Full Text] [Related]

  • 43. Evaluation of cells and biological reagents for adventitious agents using degenerate primer PCR and massively parallel sequencing.
    McClenahan SD, Uhlenhaut C, Krause PR.
    Vaccine; 2014 Dec 12; 32(52):7115-21. PubMed ID: 25454874
    [Abstract] [Full Text] [Related]

  • 44. Viral iatrogenic contamination and safety of biologicals.
    Horaud F.
    Blood Coagul Fibrinolysis; 1995 Jul 12; 6 Suppl 2():S5-9. PubMed ID: 7495969
    [Abstract] [Full Text] [Related]

  • 45. Adventitious agents from animal-derived raw materials and production systems.
    Hellman KB, Honstead JP, Vincent CK.
    Dev Biol Stand; 1996 Jul 12; 88():231-4. PubMed ID: 9119142
    [No Abstract] [Full Text] [Related]

  • 46. Theory and practice of conventional adventitious virus testing.
    Gregersen JP.
    PDA J Pharm Sci Technol; 2011 Jul 12; 65(6):634-44. PubMed ID: 22294590
    [Abstract] [Full Text] [Related]

  • 47. Review of current preclinical testing strategies for bacterial vaccines.
    Falk LA, Chandler DK, Richman P.
    Dev Biol Stand; 1998 Jul 12; 95():25-9. PubMed ID: 9855411
    [Abstract] [Full Text] [Related]

  • 48. Detection breadth and limits for potential adventitious/endogenous contaminants in biopharmaceutical processes: a reality check for innovative methods.
    Duncan P, McKerral L, Feng S, Tsai PK.
    Dev Biol (Basel); 2006 Jul 12; 126():283-90; discussion 327. PubMed ID: 17058504
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Viral risk mitigation for Mammalian cell culture media.
    Weaver B, Rosenthal S.
    PDA J Pharm Sci Technol; 2010 Jul 12; 64(5):436-9. PubMed ID: 21502048
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Current issues in viral assays and viral clearance evaluation.
    Lubiniecki AS.
    Dev Biol Stand; 1996 Jul 12; 88():9-11. PubMed ID: 9119167
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Broadening our expectations for viral safety risk mitigation.
    Kljavin IJ.
    PDA J Pharm Sci Technol; 2011 Jul 12; 65(6):645-53. PubMed ID: 22294591
    [Abstract] [Full Text] [Related]

  • 59. Human Vaccines & Immunotherapeutics: News.
    Hum Vaccin Immunother; 2017 May 04; 13(5):968-969. PubMed ID: 28509656
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.